

RESEARCH PAPER

104

BMRC Journal Vol. 50, No. 2, AUGUST 2024

Association of Serum FT₃ with Severity of Heart Failure and its Correlation with NT-proBNP

Siddika Sanjida^{1*}, Dr. Nowrose Jahan², Sk Faieq Siddique³, Tasnim Tabassum Progga⁴, Rifat Ara Chayan⁵, Masrufa Gulshan⁶

¹Department of Biochemistry, International Medical College, Gushulia, Sataish, Tongi, Gazipur, ²Department of biochemistry, Medical college for women & Hospital, ³Department of gastroenterology, Enam Medical college & Hospital, ⁴Department of Biochemistry, Asgar Ali Medical college, Gandaria, Dhaka-1204, ⁵Department of Biochemistry, Sheikh Sayera khatun medical College, Gopalganj, ⁶Department of biochemistry, Chandpur Medical College, Chandpur.

Abstract

Background: Heart failure is a global health emergency affecting millions of people worldwide and is increasing in prevalence. NT-proBNP is a hormone that is a marker of severity and prognosis of heart failure. Thyroid hormone has an important regulatory impact on the heart. Altered thyroid function specially triiodothyronine and increase NT-proBNP are highly prevalent in heart failure patients without apparent thyroid diseases.

Objectives: To evaluate the association of serum FT₃ with heart failure severity and its correlation with NT-proBNP as a potential marker.

Methods: A cross-sectional analytical study was conducted at the Department of Biochemistry, Sir Salimullah Medical College (SSMC), over a 12-month period following ethical approval. A total of 110 clinically diagnosed heart failure subjects were enrolled based on inclusion and exclusion criteria. Written informed consent was obtained from patients and detailed histories, clinical examinations and Serum FT₃, serum TSH and serum NT-proBNP were performed. Data was collected using a semi-structured questionnaire and Statistical analysis was done by using SPSS version 22.0.

Results: Serum FT₃ level was significantly lower among heart failure patients with high NT-proBNP but the mean value of serum TSH was normal. Low FT₃ level is associated with more severe heart failure patients having high NT-proBNP levels.

Conclusion: Serum FT₃ has an inverse relation with NT-proBNP in patients with heart failure. As low FT₃ associated with severe heart failure patients with high NT-proBNP, low FT₃ could be a potential marker for heart failure severity.

Keywords: Heart failure patients, serum FT₃, serum TSH, serum NT-proBNP.

Introduction:

Heart failure is a chronic progressive disorder in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. The incidence of HF in developed countries is approximately 1-2% in adult population at age 60-69 years with prevalence rising to ≥10% among persons 70 years of age.^{1,2} The HF rate is increasing in developing countries and this rising trend has also been observed in people who lead urban lifestyle.³

The projections are worrisome since it is expected >8 million people will have this condition by 2030 and the prevalence is increasing by 46%.⁴

Thyroid hormone is required for normal growth and development as well as regulating metabolism in adults.⁵ These hormones are thyroxine (T₄) and 3,3,5-triiodo-L-thyronine (T₃), which are synthesized and secreted from thyroid follicular cells.⁶ Thyroid release >85% T₄ into bloodstream, certain cells transform it into T₃ through a process called de-iodination.⁷ Thyroid hormones, specially T₃ exhibit a variety of effects on the heart and peripheral vascular system.⁸ In severe illness there is drop of serum T₃ levels and circulating TSH & T₄ usually remains within normal range.⁹ These changes are due to induction of D3 enzyme activity and reduction of D1 and D2 activation.¹⁰ D3 catalyzes

***Correspondence:** Dr. Siddika Sanjida, Department of Biochemistry, International Medical College, Gushulia, Sataish, Tongi, Gazipur
e-mail address: ridee40@gmail.com
ORCID: 0009-0008-2879-745X

the conversion of T₄ to reverse triiodothyronine (rT₃) and the conversion of T₃ to 3,3,2-diiodothyronine (T₂).¹¹ These typical changes in T₃ concentrations were called the low T₃ syndrome and is associated with a worse prognosis in heart failure.^{9,12}

NT-proBNP is an important biomarker in heart failure.¹³ It is well known that volume expansion, myocardial stretch, is a key factor of its secretion, while many neurohumoral factors also induce its secretion.¹⁴ Increased NT-proBNP level in heart failure reflected volume and disease severity.¹⁵

Suppression of thyroid axis function in heart failure contributes to impairment of cardiac pumping activity.¹⁶ That increases myocardial stretch which further increases NT-proBNP levels.

In this context, the current study has planned to evaluate the association of serum FT₃ with severity of heart failure and its correlation with NT-proBNP. It may give an idea that low FT₃ concentration plays a critical role in disease progression. Low FT₃ may serve as a valuable biomarker for risk stratification, aiding clinicians in identifying high-risk patients, as well as appropriate measures that can prevent the consequences of heart failure.

Materials and Methods:

The study was a cross-sectional analytical study conducted in the Department of Biochemistry, Sir Salimullah Medical College for a period of twelve months, extending from March 2022 to February 2023. The study was conducted among 110 clinically diagnosed heart failure patients aged up to 74 years who were admitted within 6 hours in the department of cardiology in SSMC & MH and NICVD during the study period. Patients with previously diagnosed cases of thyroid disorders or treated with thyroid medication or history of renal impairment & dialysis, liver cirrhosis, pulmonary hypertension or other lung problems, cancer, or suffering from severe infection (sepsis), or subjects with history of dopamine or steroids intake were excluded. Sampling was selected purposively after obtaining informed consent from the patients before enrollment in the study. Before starting the data collection, all patients were described about the study objective and details procedure of the study. They were clearly informed that this participation is voluntary, and they had the freedom to withdraw themselves from the study at any stage. Data was collected by history taking, clinical examination and recorded on a

standard questionnaire by the researcher. Serum NT-proBNP were done. The grouping of the study subjects were done after estimating NT-proBNP. Group-I included heart failure subjects with NT-proBNP > 2000 pg/ml and group-II included heart failure subjects with NT-proBNP 125-2000 pg/ml. Serum FT₃ level was observed between these two groups. Additional serum TSH was also done. Prior to conducting the study, ethical approval was obtained from the Institutional Review Board (IRB) of SSMC. All data was checked, coded and entered in standard statistical software version-22.0. An unpaired t test was performed to observe the mean age, any significant difference between the mean value of blood pressure and EF, the mean values of serum TSH between the study groups. The Chi square test was done to observe the status of serum FT₃ and the association between serum FT₃ with NT-proBNP in HF patients. Pearson's correlation was used to show the correlation between FT₃ and NT-proBNP in the study groups. The *p*-value of <0.05 was considered statistically significant.

Results:

A total of 110 clinically diagnosed heart failure subjects were enrolled in this study in two groups- group I and group II. Among them 55 heart failure patients with NT-proBNP > 2000 pg/ml were included in group I and 55 heart failure patients with NT-proBNP 125-2000 pg/ml were included in group II.

An Unpaired-t test was done to observe the mean age was 65.05±9.94 years in group I and 62.44±9.26 years in group I. The difference was not statistically significant (*p*>0.05) between two groups.

An Unpaired - t test was done to measure the mean SBP was 103±12.8 mmHg in group I and 101.9±12 mmHg in group II. The mean DBP was 66.9±10.2 mmHg in group I and 66.1±10.4 mmHg in group II. The difference was not statistically significant (*p*>0.05) between two groups. The mean EF was 40.8±11.7% in group I and 52.7±12.5% in group II. The difference was statistically significant (*p*<0.05) between two groups.

A Chi-square test was done to measure the level of significance. It was observed that more than one third (34.5%) of patients had low serum FT₃ (<2.3 pg/ml) in group I and 16.4% in group II. The difference was statistically significant (*p*<0.05) between two groups.

An Unpaired-t test was done to measure the mean serum TSH was 3.07±1.0 mIU/L in group I and

3.37±0.62 mIU/L in group II. All (100%) of patients had belonged to normal (0.55-4.78 mIU/L) serum TSH level in both groups. But the difference was not statistically significant ($p>0.05$) between two groups.

A Chi-square test was done to measure the association between serum FT₃ with NT-proBNP in

heart failure patients. A total of 28 patients had found low FT₃, where 2(7.1%) in 125-1200 pg/ml NT-proBNP, 8(28.6%) in 1200-3999 pg/ml and 18(64.3%) in 4000->35000 pg/ml NT-proBNP. Patients with low FT₃ level were found more in higher NT-proBNP and the difference was statistically significant ($p<0.05$).

Table I: Distribution of the study patients according to age (n=110)

Age(years)	Group I (n=55) [NT-proBNP >2000]	Group II (n=55) [NT-proBNP 125-2000]	p-value
Mean±SD	65.05±9.94	62.44±9.26	0.157 ^{ns}
Range (Min-Max)	35-74	33-74	

Values are presented as mean±SD.

p-value was determined by Unpaired-t test, ns= not significant.

Table II: Status of the study patients according to blood pressure and EF (N=110)

	Group I (n=55) [NT-proBNP >2000] Mean±SD	Group II (n=55) [NT-proBNP 125-2000] Mean±SD	p-value
SBP (mmHg)	103±12.8	101.9±12	0.642 ^{ns}
Range (Min-Max)	90-130	85-130	
DBP (mmHg)	66.9±10.2	66.1±10.4	0.684 ^{ns}
Range (Min-Max)	50-95	50-95	
EF (%)	40.8±11.7	52.7±12.5	0.001 ^s
Range (Min-Max)	21-68	28-72	

Values are presented as mean±SD

p-value was determined by Unpaired-t test, s= significant and ns= not significant.

Table III: Distribution of the study patients according to serum FT₃ (N=110)

Serum FT ₃ (pg/ml)	Group I (n=55) [NT-proBNP >2000]		Group II (n=55) [NT-proBNP 125-2000]		p-value
	n	%	n	%	
Low (<2.3)	19	34.5	9	16.4	0.028 ^s
Normal (2.3-4.1)	36	65.5	46	83.6	

Results are presented as frequency and percentage

p-value determined by Chi-square test, s= significant.

Table IV: Status of the study patients according to serum TSH (N=110)

Serum TSH (mIU/L) Normal (0.55-4.78)	Group I (n=55) [NT-proBNP >2000]	Group II (n=55) [NT-proBNP 125-2000]	p-value
Mean±SD	3.07±1.0	3.37±0.62	0.061 ^{ns}
Range (Min-Max)	1.04-4.72	1.84-4.32	

Values are presented as mean±SD

p-value was determined by Unpaired-t test, ns= not significant.

Table V: Association between serum FT₃ with NT-proBNP (N=110)

Serum FT3	NT-proBNP (pg/ml)						p-value
	125-1200 (n=38)		1201-3999 (n=35)		4000->35000 (n=37)		
	n	%	n	%	n	%	
Low	2	7.1	8	28.6	18	64.3	0.001 ^s
Normal	36	43.9	27	32.9	19	23.2	

Results are presented as frequency and percentage
p-value determined by Chi-square test, s= significant.




Figure 1: Scatter diagram showing negative significant Pearson correlation ($r = -0.419$; $r^2 = 0.18$; $p = 0.001$) between serum FT₃ with NT-proBNP.

Discussion:

This cross-sectional analytical study was carried out to evaluate the association of serum FT₃ with NT-proBNP in heart failure patients without prior thyroid dysfunction. A total of 110 subjects were included based on predefined enrollment criteria. Among them 55 were heart failure patients with NT-proBNP > 2000 pg/ml and 55 were HF patients with NT-proBNP 125-2000 pg/ml. This study was conducted in the department of Biochemistry, Sir Salimullah Medical college, Dhaka from March' 22 to February' 23 to assess the relation between FT₃ and NT-proBNP in patients with heart failure.

In this study the mean age was 65.05 ± 9.94 years in group I and 62.44 ± 9.26 years in group I. It was evident from the current study that heart failure prevalence increases from middle to old age.¹⁷⁻¹⁹

In the present study Mean SBP was (103 ± 12.8 Vs 101.9 ± 12) and mean DBP was (66.9 ± 10.2 Vs

66.1 ± 10.4) mmHg almost similar in both groups.^{20,21} Mean EF% was lower in group I than group II. There was a significant negative correlation observed between NT-proBNP level.¹¹

In accordance with the present study low serum free triiodothyronine (<2.3 pg/ml) was observed more than one third (34.5%) of patients in NT-proBNP >2000 pg/ml than 16.4% in patients with NT-proBNP 125-2000 pg/ml. Increased NT-proBNP related with low free triiodothyronine level.^{16, 22-25} Low thyroid hormone concentration, mainly low serum FT₃ concentration, is a common finding in patients with non-thyroidal illnesses, including cardiac diseases like heart failure.¹¹

The current study showed that the mean serum TSH was 3.07 ± 1.0 in group I and 3.37 ± 0.62 mIU/L in group II. It was observed that all the patients had belonged to normal TSH (0.55-4.78) level in both groups.^{9, 26-27} Normal TSH levels were common in patients with non-thyroidal illnesses.

In this study low FT₃ was observed 7.1% in NT-proBNP 125-1200 pg/ml, 28.6% in NT-proBNP 1200-3999 pg/ml and 64.3% in 4000->35000 pg/ml NT-proBNP of heart failure patients. It was evident that the percentage of low FT₃ was significantly higher in high NT-proBNP HF patients. Low free triiodothyronine was associated with severe heart failure patients with high NT-proBNP level.^{11, 28-29}

In the present study, Pearson's correlation test was done to observe the relation between serum FT₃ levels with NT-proBNP in heart failure patients. It showed a significant negative correlation between free triiodothyronine level with NT-proBNP in study subjects ($p = <0.001$).^{11,16} Increased N-terminal pro B-type natriuretic peptide level is associated with high cardiac related morbidity and mortality in patients with HF. So, this inverse relation suggests that low FT₃ is a strong predictive marker for severe heart failure patients.^{23,30-32} In this study the co-efficient of correlation was $r = -0.419$ and co-efficient of determination was $r^2 = 0.18$. That means high NT-proBNP is only 18% that is due to low FT₃.

Although our study also has some limitations such as small sample size and the absence of serial evaluation of serum TT₃ and serum FT₄ were not analyzed due to financial constraints of the study, the study population was selected from a few selected hospitals in Dhaka city with limited time span, so the result of the study may not reflect the exact picture of the country. However, this study suggests that low triiodothyronine state may produce a hypothyroid-like-syndrome that contributes to the worsening or exacerbation of the intrinsic cardiac diseases.

Conclusion:

In conclusion, serum FT₃ inversely correlated with NT-proBNP in patients with severe heart failure. Low FT₃ plays a critical role in the progression of heart failure and could potentially serve as a biomarker for risk stratification. The present study may be useful for the clinicians for risk stratification of severe heart failure patients. Additional study is needed to determine the prognosis and specific treatment with FT₃ supplementation that should be prioritized in high-risk heart failure patients.

Acknowledgements:

The authors would like to express their sincere gratitude to the guide, teachers, and colleagues for their help in data analysis and manuscript revision and editing.

Ethical Clearance: Ethical clearance taken from the Institutional Review Board (IRB) of SSMC.

Conflict of interest: There was no conflict of interest.

Funding: The study was partially financially supported by the research grant for student, Bangladesh Medical Research Council (BMRC).

Submit Date: 14 October, 2023

Final Revision Received: 01 July, 2024

Accepted: 23 February, 2024

Publication: 01 August, 2024

References:

1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovascular research*. 2022; 118:3272-3287. Doi:10.1093/cvr/cvac013.
2. Donagh TAM, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart failure journal*. 2021; 42:3599-3726. Doi:10.1093/eurheartj/ehab368.
3. Groenewegen A, Rutten HF, Mosterd A, Hoes WA. Epidemiology of heart failure. *European journal of heart failure*. 2020; 22:1342-56. Doi: 10.1002/ejhf.1858.
4. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Cardiac failure review*. 2017; 31:7-11. Doi: 10.15420/cfr.2016:25:2.
5. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. *Physiological Reviews*. 2014;94: 355-382. Doi: 10.1152/physrev.00030.
6. Jing L, Zhang Q. Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. *Frontiers in Endocrinology*. 2022; 13:992883. Doi:10.3389/fendo.2022.992883.
7. Fliers E, Kalsbeek A, Boelen A. Mechanisms in endocrinology: Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis. *European journal of endocrinology*. 2014; 171:197-208. Doi: 10.1530/EJE-14-0285.
8. Khan R, Sikanderkhal S, Gui J, Adeniyi AR, O'Dell K, Erickson M, et al. Thyroid and Cardiovascular Disease: A Focused

- Review on the Impact of Hyperthyroidism in Heart Failure. *Cardiology research*. 2020; 11:68–75. Doi:10.14740/cr1034.
9. Fliers E, Boelen A. An update on non-thyroidal illness syndrome. *Journal of endocrinological investigation*. 2021; 44:1597–1607. Doi:10.1007/s40618-020-01482-4.
 10. Janssen R, Muller A, Simonides WS. Cardiac thyroid hormone metabolism and heart failure. *European thyroid journal*. 2017; 6:130-137. Doi:10.1159/000469708.
 11. Takahashi H, Kashiwagi Y, Nagoshi T, Tanaka Y, Oi Y, Kimura H, Minai K, Yoshimura M. Low triiodothyronine levels correlate with high B-type natriuretic peptide levels in patients with heart failure. Division of cardiology, Department of internal medicine. 2021; 11:21865. Doi:10.1038/s41598-021-01454-5.
 12. Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid hormones and cardiovascular function and diseases. *Journal of the American college of cardiology*. 2018; 71:1781-1796. Doi: 10.1016/j.jacc.2018.02.045.
 13. Brozaitiene J, Mickuviene N, Podlipskyte A, Burkauskas J, Bunevicius R. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type Natriuretic peptide for patients after acute coronary syndrome: A longitudinal observational study. *BMC cardiovascular disorder*. 2016; 16:3047. Doi: 10.1186/s12872-016-0226-2
 14. Tominaga M, Kawai M, Minai K, Ogawa K, Inoue Y, Morimoto S, et al. Association between plasma B-type natriuretic peptide and anaemia in heart failure with or without ischaemic heart disease: a retrospective study. *Cardiovascular medicine Research*. 2019; 9: e024194. Doi:10.1136/bmjopen-2018- 024194.
 15. Castiglione V, Aimò A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. *Heart failure Rev*. 2022; 27:625-43. Doi: 10.1007/s10741-021-10105-w.
 16. Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. *National institutes of health of public access*. 2012; 110:234-39. Doi: 10.1016/j.amjcard.2012.02.068.
 17. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett Jr JC, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages. *Circulation*. 2007; 115: 1563-70. Doi: 10.1161/Circulationaha.106.666818.
 18. Kitzman DW, Rich MW. Age disparities in heart failure research. *Journal of the American medical association*. 2010; 304:1950-51. Doi: 10.1001/jama.2010.1592.
 19. Uchmanowicz I, Nessler J, Gobbens R, Gackowski A, Kurpas D, Straburzynsk-Migaj E, et al. Coexisting frailty with heart failure. *Frontiers in physiology*. 2019; 10:791. Doi: 10.3389/fphys.2019.00791.
 20. Franklin SS, Levy D. Aging, blood pressure, and heart failure: what are the connections? *Hypertension*. 2011; 58:760–762. Doi:10.1161/hypertensionaha.111.179119.
 21. Cautela J, Tartiere J-M, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. *European journal of heart failure*. 2020; 22:1357-1365. Doi: 10.1002/ehf.1835.
 22. Passino C, Pingitore A, Landi P, Fontana M, Clerico A, Emdin M, Iervasi G. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. *Journal of cardiac failure*. 2009; 15:35-40. Doi: 10.1016/j.cardfail.2008.08.008.
 23. Brozaitiene J, Mickuviene N, Podlipskyte A, Burkauskas J, Bunevicius R. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type Natriuretic peptide for patients after acute coronary syndrome: A longitudinal observational study. *BMC cardiovascular disorder*. 2016; 16:3047. Doi: 10.1186/s12872-016-0226-2.
 24. Kazukauskienė N, Skiriute D, Gustiene O, Burkauskas J, Zaliunaite V, Mickuviene N, Brozaitiene J. Importance of thyroid hormone level and genetic variations in deiodinases for patients after acute myocardial infarction: A longitudinal observational study. *Scientific reports*. 2020; 10:19169. Doi: 10.1038/s41598-020-66006-9.
 25. Yamakawa H, Kato TS, Noh JY, Yuasa S, Kawamura A, Fukuda K, Aizawa Y. Thyroid hormone plays an important role in cardiac function: From bench to bedside. *Frontiers in Physiology*. 2021; 12:606931. Doi: 10.3389/fphys.2021.606931.
 26. Iervasi G, Pingitore A, Landi P, Racit M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome. *Research article*. 2003; 107:708-13. Doi: 10.1161/01.cir.0000048124.64204.3f.
 27. Jucha FM, Rubinkiewicz ZK, Kabat M, Plens K, Rychlak R, Nessler J, Gackowski A. Low triiodothyronine syndrome and selenium deficiency- undervalued players in advanced heart failure? A single center pilot study. *BMC Cardiovascular Disorders*. 2019; 3:133. Doi: 10.1186/s12872-019-1076-5.
 28. Rothberger DG, Gadhvi S, Michelakis N, Kumar A, Calixte R, Shapiro EL. Usefulness of serum triiodothyronine (T3) to predict outcome in patients hospitalized with acute heart failure. *Heart disease*. 2017; 119:599-603. Doi: 10.1016/j.amjcard.2016.10.045.
 29. Yuko Y, Shoji T, Miyashima M, Nagata Y, Kakutani Y, Ochi A, et al. Low free triiodothyronine level as a predictor of

- cardiovascular events and all-cause mortality in patients undergoing hemodialysis: The dream cohort. *Japan Atherosclerosis and Thrombosis*. 2021; 28:1071-1082. Doi:10.5551/jat.60624.
30. Pfister R, Strack N, Wielckens K, Malchau G, Erdmann E, Scneider C.A. The relationship and prognostic impact of low -T3 syndrome and NT-proBNP in cardiovascular patients. *International journal of cardiology*. 2009; 144: 187-190. Doi: 10.1016/j.ijcard.2009.03.137.
 31. Wang K, Wang W, Zhang K, Gao J, Liu Y, Zheng J, Li P, Tang Y. Prognostic value of free triiodothyronine and N-terminal pro-B-type natriuretic peptide for patients with acute myocardial infarction undergoing percutaneous coronary intervention: a prospective cohort study. *Annals of Translational Medicine*. 2021; 9:294. Doi: 10.21037/atm-20-5541.
 32. Zhao X, Zhang R, Jiang H, Liu K, Ma C, Bai M, An T, et al. Combined use of low T3 syndrome and NT-proBNP as predictors for death in patients with acute decompensated heart failure. *BMC endocrine disorders*. 2021; 21. Doi.:10.1186/s12902-021-00801-x